Author: OurCrowd

[MeMed in MeMed] MeMed awarded $2 million grant to establish a first-of-Its-kind acute care digital and physical biobank

HAIFA, Israel, Jan. 12, 2026 /PRNewswire/ — MeMed, the leader in host-response diagnostics, announced it has been awarded a competitive national grant through the IIA to establish an acute-care diagnostics and proteomics biobank, as part of a nationwide AI R&D data infrastructure. This initiative significantly accelerates the development and validation of next-generation AIVD™ (Artificial Intelligence In Vitro Diagnostics) for high-risk patients by combining acute-care biospecimens with linked clinical data and high-resolution immune profiling. Read more...

Read More

[Alloy Therapeutics in BusinessWire] Swiss Rockets Group and Alloy Therapeutics partner to advance radioligand therapeutics in oncology

BOSTON & BASEL, Switzerland–(BUSINESS WIRE)–Swiss Rockets AG and Alloy Therapeutics, Inc. today announced the signing of a Master Research Agreement (MRA) establishing a multi-target collaboration to discover and develop next-generation radioligand therapeutics (RLTs) for oncology. The collaboration will be executed through Swiss Rockets’ radiotherapeutics subsidiary, Torpedo Pharmaceuticals AG. Read more...

Read More